Table 1 Characteristics and clinical outcome of patients undergoing pancreatic surgery before and during the COVID lockdown period.Ordinal data presented as median (25;75 quartiles)
Before lockdown | ||||||
|---|---|---|---|---|---|---|
2017/2018 | 2018/2019 | 2019/2020 | Total | Lockdown | p value | |
Numbers | 254 | 253 | 232 | 739 | 242 | 0.851 |
Males/females | 153/101 | 137/116 | 123/109 | 415/326 | 140/102 | |
Age, years | 69 (62;73) | 67 (58;73) | 69 (61;74) | 68 (60;73) | 68 (59;75) | 0.140 |
ASA (%) | ||||||
1–2 | 123 (48.4) | 141 (55.7) | 92 (39.7) | 356 (48.2) | 101 (41.7) | 0.088 |
3 | 129 (50.8) | 111 (43.9) | 139 (59.9) | 379 (51.3) | 141 (58.3) | 0.064 |
4 | 2 (0.8) | 1 (0.4) | 1 (0.4) | 4 (0.5) | 0 | 0.577 |
Charlson score (%) | ||||||
0–1 | 160 (63.0) | 161 (63.6) | 147 (63.4) | 468 (63.3) | 139 (57.4) | 0.110 |
2–3 | 69 (27.2) | 74 (29.3) | 60 (25.9) | 203 (27.5) | 73 (52.5) | 0.412 |
> 3 | 25 (9.9) | 18 (7.1) | 25 (10.8) | 68 (9.2) | 30 (12.4) | 0.174 |
Waiting time (days) | ||||||
All patients | 31 (24;39) | 29 (21;41) | 28 (20;36) | 30 (21;39) | 29 (21;37) | 0.895 |
Malignant tumor | 31 (23;37) | 28 (19;39) | 27 (20;35) | 28 (21;37) | 28 (21;35) | 0.294 |
NET | 27 (13;32) | 32 (24;42) | 34 (26;42) | 30 (24;40) | 38 (25;52) | 0.076 |
Benign disease | 33 (29;45) | 39 (24;49) | 29 (20;41) | 32 (23;46) | 38 (20;65) | 0.134 |
Length of stay (days)* | 10 (7;17) | 10 (7;17) | 10 (8;16) | 10 (7;17) | 11 (6;18) | |
30-day mortality (%) | 5 (2.0) | 4 (1.6) | 3 (1.3)12 (1.6) | 5 (2.1) | 0.582 | |
90-days mortality (%) | 14 (5.5) | 13 (5.1) | 12 (5.2)39 (5.3) | 18 (7.4) | 0.209 | |
In-hospital deaths (%) | 5 (2.0) | 4 (1.6) | 3 (1.3) 12 (1.6) | 5 (2.1) | 0.582 | |